Compare TXT & IXHL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | TXT | IXHL |
|---|---|---|
| Founded | 1923 | 2001 |
| Country | United States | Australia |
| Employees | N/A | N/A |
| Industry | Aerospace | |
| Sector | Industrials | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 14.5B | 49.1M |
| IPO Year | N/A | N/A |
| Metric | TXT | IXHL |
|---|---|---|
| Price | $87.30 | $0.43 |
| Analyst Decision | Buy | |
| Analyst Count | 12 | 0 |
| Target Price | ★ $92.33 | N/A |
| AVG Volume (30 Days) | 1.2M | ★ 24.8M |
| Earning Date | 01-21-2026 | 11-14-2025 |
| Dividend Yield | ★ 0.09% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 4.55 | N/A |
| Revenue | ★ $14,237,000,000.00 | $12,000.00 |
| Revenue This Year | $8.63 | N/A |
| Revenue Next Year | $4.95 | N/A |
| P/E Ratio | $19.18 | ★ N/A |
| Revenue Growth | ★ 1.83 | N/A |
| 52 Week Low | $57.70 | $0.08 |
| 52 Week High | $88.12 | $2.25 |
| Indicator | TXT | IXHL |
|---|---|---|
| Relative Strength Index (RSI) | 71.16 | 57.22 |
| Support Level | $82.23 | $0.38 |
| Resistance Level | $84.49 | $0.50 |
| Average True Range (ATR) | 1.44 | 0.04 |
| MACD | 0.53 | 0.01 |
| Stochastic Oscillator | 90.78 | 63.35 |
Textron is a conglomerate that designs, manufactures, and services a range of specialty aircraft including small jets, propeller-driven airplanes, helicopters, and tilt-rotor aircraft. Textron Aviation manufactures and services Cessna and Beechcraft planes. Bell is a helicopter and tilt-rotor manufacturer and servicer for both commercial and military customers. Textron Systems produces uncrewed aircraft and armored vehicles for the military market as well as aircraft simulators and training for the commercial and military markets. Textron Industrial contains the Kautex business, which manufactures plastic fuel tanks for conventional and hybrid motor vehicles, and other subsidiaries that produce specialized vehicles such as golf carts and all-terrain vehicles.
Incannex Healthcare Inc is a clinical stage pharmaceutical company developing medical cannabis products for the treatment of Obstructive Sleep Apnea (OSA), Traumatic Brain Injury (TBI)/Concussion, Rheumatoid Arthritis, Inflammatory Bowel Disease, and Inflammatory Lung Conditions. The company has an Australian license to import, export, and distribute medicinal cannabis products and has launched a line of cannabinoid products. The Company operates and manages its business as one reportable and operating segment, which is the Research and Development of the use of psychedelic medicine and therapies.